Trials to watch: Phase III BCG naïve non-muscle invasive bladder cancer [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
More than four decades later, BCG remains the standard of care (SoC) and the most effective therapy for these patients, with recent studies suggesting it to be effective in at least 70% of patients to prevent recurrence, while some experts predict the number may be even higher, potentially even closer to 80%. Given its high levels of efficacy, sponsors are investigating combination therapies including BCG to see if immunotherapies can boost that well-established effectiveness. There have, however, been difficulties in the past decade as only Merck is producing BCG, leading to ongoing shortages. Questions are being raised about this, given the high-level adverse events that patients suffer on immune checkpoint inhibitors and chemotherapies, as well as the cost factor. With the already high response of BCG alone, and given recently approved gene therapies and others that are in the pipeline, some experts are taking issue with these approaches. Despite these concerns, sponsors are
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Summit Therapeutics downgraded at Citi on valuation [Seeking Alpha]Seeking Alpha
- MRK's Keytruda Combo Fails in Phase III Colorectal Cancer Study [Yahoo! Finance]Yahoo! Finance
- Merck to Present New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024Business Wire
- Merck & Co. Inc. (MRK): A Good Undervalued Blue Chip Stock to Buy According to Analysts [Yahoo! Finance]Yahoo! Finance
- Merck's colorectal cancer therapy fails late-stage trial [CNBC]CNBC
MRK
Earnings
- 7/30/24 - Beat
MRK
Sec Filings
- 8/6/24 - Form 4
- 8/5/24 - Form 10-Q
- 7/30/24 - Form 8-K
- MRK's page on the SEC website